業績

論文【共著を含む】

1. Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Feb;21(2):242-249. [31838011]
2. Tateishi A, Ishiki H, Kubo E, Satomi E. EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial. J Clin Oncol. 2020 Jan 20;38(3):285-286.Epub 2019 Dec 5. [31804860]
3. Matsuoka H, Iwase S, Miyaji T, Kawaguchi T, Ariyoshi K, Oyamada S, Satomi E, Ishiki H, Hasuo H, Sakuma H, Tokoro A, Shinomiya T, Otani H, Ohtake Y, Tsukuura H, Matsumoto Y, Hasegawa Y, Kataoka Y, Otsuka M, Sakai K, Matsuda Y, Morita T, Koyama A, Yamaguchi T. Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08). J Pain Symptom Manage. 2019 Oct;58(4):645-653. [31254640]
4. Matsuoka H, Agar M, Vandersman Z, Good P, Fazekas B, Brown L, Hardy J, Weil J, Currow DC. Harms From Haloperidol for Symptom Management in Palliative Care-a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies. J Pain Symptom Manage. 2019 Sep;58(3):e6-e8. [31121249]
5. Matsuoka H, Allingham S, Fazekas B, Brown L, Vandersman Z, Clark K, Agar MR, Currow DC. Comparability of the Australian National Cancer Symptom Trials (CST) Group's Study Populations to National Referrals to Non-CST Specialist Palliative Care Services Participating in the Palliative Care Outcomes Collaboration. J Pain Symptom Manage. 2019 Jan;57(1):e9-e14. [30273716]　
6. Matsuoka H, Tagami K, Ariyoshi K, Oyamada S, Kizawa Y, Inoue A, Koyama A. Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: a nationwide cross-sectional survey. Jpn J Clin Oncol. 2019 May 1;49(5):486-490. [30793161]
7. Matsuoka H, Iwase S, Miyaji T, Kawaguchi T, Ariyoshi K, Oyamada S, Satomi E, Ishiki H, Hasuo H, Sakuma H, Tokoro A, Matsuda Y, Tahara K, Otani H, Ohtake Y, Tsukuura H, Matsumoto Y, Hasegawa Y, Kataoka Y, Otsuka M, Sakai K, Nakura M, Morita T, Yamaguchi T, Koyama A. Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial-JORTC-PAL08 (DIRECT) study. Support Care Cancer. 2020 Jun;28(6):2931-2939. [31761974]　
8. Sadahiro R, Knight B, James F, Hannon E, Charity J, Daniels IR, Burrage J, Knox O, Crawford B, Smart NJ, Mill J. Major surgery induces acute changes in measured DNA methylation associated with immune response pathways. Sci Rep. 2020 Apr 1;10(1):5743. [32238836]
9. Matsuoka H, Iwase S, Miyaji T, Kawaguchi T, Ariyoshi K, Oyamada S, Satomi E, Ishiki H, Hasuo H, Sakuma H, Tokoro A, Matsuda Y, Tahara K, Otani H, Ohtake Y, Tsukuura H, Matsumoto Y, Hasegawa Y, Kataoka Y, Otsuka M, Sakai K, Nakura M, Morita T, Yamaguchi T, Koyama A. Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial-JORTC-PAL08 (DIRECT) study. Support Care Cancer. 2020 Jun;28(6):2931-2939. Epub 2019 Nov 25. [31761974]
10. Hashimoto H, Iwasa S, Yanai-Takahashi T, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Yamazaki N, Kato Y. Randomized, Double-Blind, Placebo-Controlled Phase II Study on the Efficacy and Safety of Vitamin K1 Ointment for Cetuximab or Panitumumab-Induced Acneiform Eruptions-VIKTORIA Study. Gan To Kagaku Ryoho. 2020 Jun;47(6):933-939. [32541171]
11. Tateishi A, Matsumoto Y, Tanaka M, Nakai T, Sasada S, Aoshima M, Tsuchida T. The utility of transbronchial rebiopsy for peripheral pulmonary lesions in patients with advanced non-squamous non-small cell lung cancer. BMC Pulm Med. 2020 Sep 9;20(1):238. [32907572]
12. Matsuoka H, Morita T, Oyamada S, Yamaguchi T, Koyama A. Between-group difference in mean values or changes in pain intensity? Evaluating the distribution of change from baseline in a neuropathic cancer pain clinical trial. Ann Palliat Med. 2020 Nov;9(6):4398-4402. Epub 2020 Oct 21. [33081474]
13. Ishiki H, Hamano J, Nagaoka H, Matsuda Y, Tokoro A, Matsuoka H, Izumi H, Sakashita A, Kizawa Y, Oyamada S, Yamaguchi T, Iwase S. Prevalence of Extrapyramidal Symptoms in Cancer Patients Referred to Palliative Care: A Multicenter Observational Study (JORTC PAL12). Am J Hosp Palliat Care. 2021 Jul;38(7):823-829. Epub 2020 Sep 17. [32940536]
14. Tateishi A, Okuma Y. Onco-biome in pharmacotherapy for lung cancer: a narrative review. Transl Lung Cancer Res. 2022 Nov;11(11):2332-2345. [36519027]
15. Ueno T, Yatsuoka W, Ishiki H, Miyano K, Uezono Y. Effects of an oral mucosa protective formulation on chemotherapy- and/or radiotherapy-induced oral mucositis: a prospective study. BMC Cancer. 2022 Jan 21;22(1):90. [35062896]
16. Tateishi A, Goto Y. [Cancer Therapy Targeting Fusion Genes in Lung Cancer]. Gan To Kagaku Ryoho. 2022 Oct;49(10):1043-1047. Japanese. [36281592]
17. Tateishi A, Horinouchi H, Yoshida T, Masuda K, Jo H, Shinno Y, Okuma Y, Goto Y, Yamamoto N, Ohe Y. Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer. Respir Investig. 2022 Mar;60(2):234-240. Epub 2021 Dec 28. [34972681]
18. Ishiki H, Hasuo H, Matsuda Y, Matsuoka H, Hiramoto S, Higuchi M, Yoshida K, Tokoro A, Hatano Y, Hori T, Kinkawa J, Nojima M. Prevalence of Myofascial Pain Syndrome and Efficacy of Trigger Point Injection in Patients with Incurable Cancer: A Multicenter, Prospective Observational Study (MyCar Study). Pain Med. 2022 Jul 1;23(7):1259-1265. [34940848]
19. Matsuoka H, Clark K, Fazekas B, Oyamada S, Brown L, Ishiki H, Matsuda Y, Hasuo H, Ariyoshi K, Lee J, Le B, Allcroft P, Kochovska S, Fujiwara N, Miyaji T, Lovell M, Agar M, Yamaguchi T, Satomi E, Iwase S, Phillips J, Koyama A, Currow DC. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ Open. 2022 Feb 7;12(2):e050182. [35131817]
20. Sadahiro R, Wada S, Matsuoka YJ, Uchitomi Y, Yamaguchi T, Sato T, Esaki M, Yoshimoto S, Daiko H, Kanemitsu Y, Kawai A, Kato T, Fujimoto H, Uezono Y, Shimizu K, Matsuoka H. Prevention of delirium with agitation by yokukansan in older adults after cancer surgery. Jpn J Clin Oncol. 2022 Nov 3;52(11):1276-1281. [35907781]
21. Yanai Y, Makihara RA, Matsunaga N, Shimizu R, Tominaga S, Hoshino S, Nishibuchi Y, Maruki Y, Ohba A, Shimizu K, Okusaka T. A feasibility study of a peer discussion group intervention for patients with pancreatobiliary cancer and their caregivers. Palliat Support Care. 2022 Aug;20(4):527-534. [34593073]
22. Ishiki H, Hirayama T, Horiguchi S, Iida I, Kurimoto T, Asanabe M, Nakajima M, Sugisawa A, Mori A, Kojima Y, Udagawa R, Tsuchiya H, Oki M, Shimizu M, Yanai Y, Touma S, Nozawa K, Kojima R, Inamura N, Maehara A, Suzuki T, Satomi E; AYA Support Team, NCCH. A Support System for Adolescent and Young Adult Patients with Cancer at a Comprehensive Cancer Center. JMA J. 2022 Jan 17;5(1):44-54. Epub 2021 Dec 15. [35224259]
23. Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Sakai K, Yoshida T, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takeda M, Okuno T, Takegawa N, Haratani K, Koyama A, Nishio K, Nakagawa K. Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study). Oncologist. 2023 Mar 17;28(3):278-e166. [36426809]
24. Sadahiro R, Matsuoka LN, Zeng BS, Chen KH, Zeng BY, Wang HY, Chu CS, Stubbs B, Su KP, Tu YK, Wu YC, Lin PY, Chen TY, Chen YW, Suen MW, Hopwood M, Yang WC, Sun CK, Cheng YS, Shiue YL, Hung CM, Matsuoka YJ, Tseng PT. Black cohosh extracts in women with menopausal symptoms: an updated pairwise meta-analysis. Menopause. 2023 Jul 1;30(7):766-773. [37192826]
25. Sadahiro R, Hatta K, Yamaguchi T, Masanori E, Matsuda Y, Ogawa A, Iwata Y, Tokoro A, Nakahara R, Hirayama T, Yanai Y, Ogawa Y, Kayano A, Ariyoshi K, Oyamada S, Uchitomi Y, Akechi T, Yamamoto N, Okita N, Yorikane E, Shimada K, Furukawa T, Hashimoto H, Maeda M, Sato T, Sekimoto A, Sasaki C, Saito E, Uezono Y, Matsuoka H. A multi-centre, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of ramelteon for the prevention of postoperative delirium in elderly cancer patients: a study protocol for JORTC-PON2/J-SUPPORT2103/NCCH2103. Jpn J Clin Oncol. 2023 Aug 30;53(9):851-857. [37340766]
26. Ishiki H, Kikawa Y, Terada M, Mizusawa J, Honda M, Iwatani T, Mizutani T, Mori K, Nakamura N, Miyaji T, Yamaguchi T, Ando M, Nakamura K, Fukuda H, Kiyota N; PRO/QOL research Committee of Japan Clinical Oncology Group. Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy. Jpn J Clin Oncol. 2023 Mar 7;53(3):195-202. [36702740]
27. Ishiki H, Kikawa Y, Terada M, Mizusawa J, Honda M, Iwatani T, Mizutani T, Mori K, Nakamura N, Miyaji T, Yamaguchi T, Ando M, Nakamura K, Fukuda H, Kiyota N; PRO/QOL research Committee of Japan Clinical Oncology Group. Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy. Jpn J Clin Oncol. 2023 Mar 7;53(3):195-202. [36702740]
28. Satomi E, Kobayashi T, Ishikawa A, Arakawa S, Ishiki H, Amano K, Sakiyama N, Ariyoshi K, Kihara K, Oyamada S, Mizushima A. Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study. BMJ Open. 2024 Feb 27;14(2):e076575. [38417963]
29. Matsuoka H, Takeuchi E, Kato M. Physical symptoms in prolonged grief disorder: a case report. Ann Palliat Med. 2024 Nov;13(6):1530-1536. [39168644]
30. Tateishi A, Okuma Y, Goto Y, Arakaki M, Igawa YS, Torasawa M, Shinno Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice. Anticancer Res. 2024 Dec;44(12):5501-5513. [39626947]
31. Sadahiro R, Ohbuchi K, Nakaya T, Manabe S, Wada S, Yamaguchi T, Sugimoto M, Shimizu K, Sato T, Esaki M, Daiko H, Yoshimoto S, Kanemitsu Y, Kawai A, Ishikawa M, Matsui Y, Aoki K, Ueno T, Matsuoka H, Uezono Y. Metabolome Profiling of Yokukansan in Preventing Postoperative Delirium in Elderly Cancer Patients: A Reverse Translational Study. Psychiatry Clin Neurosci. 2025 Aug 5. [40765131]
32. Tateishi A, Horinouchi H, Kouno N, Takeda K, Takasawa K, Mizuno T, Okubo Y, Yoshida Y, Miyake M, Kusumoto M, Inaba K, Igaki H, Yatabe Y, Mukai M, Mihara N, Nishino J, Kuchiba A, Shibata T, Shiraishi K, Watanabe SI, Komatsu M, Kohno T, Ohe Y, Hamamoto R. Prediction recurrence in stage I epidermal growth factor receptor-mutated non-small cell lung cancer using multi-modal data. Lung Cancer. 2025 Sep;207:108727. [40876064]